Editorials
| Translational Cancer Research - Message from the Editor-in-Chief | PDF HTML |
| Eric Y Chuang, Sc.D. | |
| Pages: 1 |
| DNA-PK targeting virotherapy, a promising approach | PDF HTML |
| Koji Tsuboi | |
| Pages: 2-3 |
| Inhibitors of DNA repair for cancer therapy, ready for prime time? | PDF HTML |
| Chuan-Yuan Li | |
| Pages: 4-5 |
Original Article
| Oncolytic virus-mediated tumor radiosensitization in mice through DNA-PKcs-specific shRNA | PDF HTML |
| Takashi Kon, Xiuwu Zhang, Qian Huang, Zhonghui Yang, Shanling Liu, Bin Yan, Fang Li, He Wang, Chuan-Yuan Li | |
| Pages: 6-14 |
Review Articles
| SIRT2 is a tumor suppressor that connects aging, acetylome, cell cycle signaling, and carcinogenesis | PDF HTML |
| Seong-Hoon Park, Yuming Zhu, Ozkan Ozden, Hyun-Seok Kim, Haiyan Jiang, Chu-Xia Deng, David Gius, Athanassios Vassilopoulos | |
| Pages: 15-21 |
| Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment | PDF HTML |
| Feng-Ming Hsu, Shichuan Zhang, Benjamin P.C. Chen | |
| Pages: 22-34 |
| Normal tissue protection for improving radiotherapy: where are the Gaps? | PDF HTML |
| Pataje G.S. Prasanna, Helen B. Stone, Rosemary S. Wong, Jacek Capala, Eric J. Bernhard, Bhadrasain Vikram, C. N. Coleman | |
| Pages: 35-48 |
Perspective
| Anti-HER2 therapies: when more is more | PDF HTML |
| Monica Arnedos, Britta Weigelt, Jorge S. Reis-Filho | |
| Pages: 49-54 |
Research Highlights
| Bevacizumab: where do we go from here in breast cancer? | PDF HTML |
| Faina Nakhlis, Mehra Golshan | |
| Pages: 55-56 |
| Neoadjuvant bevacizumab and chemotherapy in breast cancer | PDF HTML |
| Suparna B. Wedam, Sherry X. Yang | |
| Pages: 57-58 |